Condition: Mesothelioma · Pancreatic Cancer · NSCLC (Advanced Non-small Cell Lung Cancer) · Sponsor: Orion Corporation, Orion Pharma
An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
This description comes directly from the study's public registry record.
Clinical Study Director · +358104261 · clinicaltrials@orionpharma.com
Always discuss trial participation with your own doctor first.
| NEXT Oncology | Irving, Texas, United States | Recruiting |
| NEXT Oncology Virginia | Fairfax, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07563738